CN100335464C - 芳烷基－四氢－吡啶,其制备方法及含有它们的药物组合物 - Google Patents

芳烷基－四氢－吡啶,其制备方法及含有它们的药物组合物 Download PDF

Info

Publication number
CN100335464C
CN100335464C CNB028207548A CN02820754A CN100335464C CN 100335464 C CN100335464 C CN 100335464C CN B028207548 A CNB028207548 A CN B028207548A CN 02820754 A CN02820754 A CN 02820754A CN 100335464 C CN100335464 C CN 100335464C
Authority
CN
China
Prior art keywords
compound
tetrahydropyridine
general formula
ethyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028207548A
Other languages
English (en)
Chinese (zh)
Other versions
CN1571770A (zh
Inventor
M·巴罗尼
B·宝利
R·卡达蒙
P·卡塞拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA, Sanofi Aventis France filed Critical Sanofi Synthelabo SA
Publication of CN1571770A publication Critical patent/CN1571770A/zh
Application granted granted Critical
Publication of CN100335464C publication Critical patent/CN100335464C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
CNB028207548A 2001-10-18 2002-10-14 芳烷基－四氢－吡啶,其制备方法及含有它们的药物组合物 Expired - Fee Related CN100335464C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0113469A FR2831166B1 (fr) 2001-10-18 2001-10-18 Aralkyl-tetrahydro-pyridines, leur preparation et compositions pharmaceutiques les contenant
FR01/13469 2001-10-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2007101368627A Division CN101096337A (zh) 2001-10-18 2002-10-14 芳烷基羧酸、其制备方法及用途

Publications (2)

Publication Number Publication Date
CN1571770A CN1571770A (zh) 2005-01-26
CN100335464C true CN100335464C (zh) 2007-09-05

Family

ID=8868455

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB028207548A Expired - Fee Related CN100335464C (zh) 2001-10-18 2002-10-14 芳烷基－四氢－吡啶,其制备方法及含有它们的药物组合物
CNA2007101368627A Pending CN101096337A (zh) 2001-10-18 2002-10-14 芳烷基羧酸、其制备方法及用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007101368627A Pending CN101096337A (zh) 2001-10-18 2002-10-14 芳烷基羧酸、其制备方法及用途

Country Status (21)

Country Link
US (2) US7326723B2 (enExample)
EP (1) EP1438291B1 (enExample)
JP (2) JP4524107B2 (enExample)
KR (1) KR100935787B1 (enExample)
CN (2) CN100335464C (enExample)
AT (1) ATE303991T1 (enExample)
AU (1) AU2002360117B2 (enExample)
BR (1) BR0213359A (enExample)
CA (1) CA2460822C (enExample)
DE (1) DE60206068T2 (enExample)
EA (1) EA007324B1 (enExample)
FR (1) FR2831166B1 (enExample)
HU (1) HUP0401713A3 (enExample)
IL (2) IL160820A0 (enExample)
IS (1) IS2486B (enExample)
MX (1) MXPA04003568A (enExample)
NO (1) NO326490B1 (enExample)
NZ (1) NZ531846A (enExample)
PL (1) PL368802A1 (enExample)
WO (1) WO2003033466A1 (enExample)
ZA (1) ZA200402059B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0402332A3 (en) 2001-10-15 2009-07-28 Janssen Pharmaceutica Nv Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage and pharmaceutical compositions containing them
US7410971B2 (en) * 2003-12-26 2008-08-12 Eisai R&D Management Co., Ltd. 1,2-di(cyclic)substituted benzene compounds
MY140489A (en) * 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
CN100526301C (zh) * 2003-12-26 2009-08-12 卫材R&D管理有限公司 1,2-二(环式基)取代苯化合物
US20060276465A1 (en) * 2003-12-26 2006-12-07 Eisai R&D Management Co., Ltd. 1,2-di(cyclic) substituted benzene compounds
WO2006068058A1 (ja) 2004-12-20 2006-06-29 Eisai R & D Management Co., Ltd. １－シクロプロピルメチル－４－［２－（３，３，５，５－テトラメチルシクロヘキシル）フェニル］ピペラジンの塩および結晶
MY144974A (en) * 2005-06-14 2011-11-30 Eisai R&D Man Co Ltd 1,2-di(cyclic) substituted benzene derivatives
US9493383B2 (en) 2005-09-15 2016-11-15 Lg Chem, Ltd. Organic compound and organic light emitting device using the same
US9608205B2 (en) 2005-09-15 2017-03-28 Lg Chem, Ltd. Organic compound and organic light emitting device using the same
US8298683B2 (en) * 2005-09-15 2012-10-30 Lg Chem, Ltd. Organic compound and organic light emitting device using the same
CN107267384B (zh) * 2008-06-05 2020-11-27 因维沃科学有限公司 用于高通量试验的三维组织

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281606A (en) * 1990-05-23 1994-01-25 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3804878A (en) * 1969-09-08 1974-04-16 Ciba Geigy Corp Hydrogenated araliphatic acids
CA2037669A1 (en) * 1990-03-12 1991-09-13 Noriki Ito Urea derivatives and salts thereof, pharmaceutical compositions containing the same, and methods for producing the same
DE69520360T2 (de) * 1994-07-04 2001-08-09 Takeda Chemical Industries, Ltd. Phosphonsäure verbindungen imre herstellung und verwendung
FR2734819B1 (fr) * 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2762514B1 (fr) * 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
US6070784A (en) * 1998-07-08 2000-06-06 The Boeing Company Contact backup roller approach to FSW process
TR200201075T2 (tr) * 1999-10-22 2002-11-21 Sanofi-Synthelabo Fenil-ve piridil-tetrahidropiridinler, bunların preparasyonu için proses ve bunları ihtiva eden farmasötik kompozisyonlar
TR200402408T4 (tr) * 1999-12-30 2004-12-21 H. Lundbeck A/S 4-fenil-1-piperazinil,-piperidinil ve-tetrahidropiridil türevleri
FR2803593B1 (fr) * 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2823749B1 (fr) * 2001-04-20 2004-02-20 Sanofi Synthelabo Phenyl- et pyridyl-piperidines, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2002085888A1 (fr) * 2001-04-20 2002-10-31 Sanofi-Synthelabo Tetrahydropyridyl-alkyl-heterocycles, procede pour leur preparation et compositions pharmaceutiques les contenants
JP3687912B2 (ja) * 2002-08-29 2005-08-24 東芝テック株式会社 プリンタユニット

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281606A (en) * 1990-05-23 1994-01-25 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The neuroprotective agent SR57746A abrogantsexperimental autoimmune encephalomyelitis and impairsassociated blood-brain barrier disruption : Implications formultiple sclerosis treatment BORRIE ET AL,PROC. NATL. ACAD. SCI. USA,Vol.96 No.22 1999 *

Also Published As

Publication number Publication date
KR20050036866A (ko) 2005-04-20
HUP0401713A2 (hu) 2004-12-28
CN1571770A (zh) 2005-01-26
ATE303991T1 (de) 2005-09-15
NZ531846A (en) 2005-10-28
DE60206068D1 (de) 2005-10-13
EA200400323A1 (ru) 2004-10-28
IL160820A (en) 2009-06-15
EP1438291B1 (fr) 2005-09-07
KR100935787B1 (ko) 2010-01-06
CN101096337A (zh) 2008-01-02
EA007324B1 (ru) 2006-08-25
AU2002360117B2 (en) 2008-07-17
US20050014795A1 (en) 2005-01-20
MXPA04003568A (es) 2004-07-30
NO326490B1 (no) 2008-12-15
PL368802A1 (en) 2005-04-04
HK1065543A1 (en) 2005-02-25
US7326723B2 (en) 2008-02-05
NO20041573L (no) 2004-07-07
IS2486B (is) 2008-12-15
CA2460822C (en) 2011-01-04
CA2460822A1 (en) 2003-04-24
US7858824B2 (en) 2010-12-28
BR0213359A (pt) 2004-10-26
JP2010120961A (ja) 2010-06-03
IL160820A0 (en) 2004-08-31
JP4524107B2 (ja) 2010-08-11
IS7181A (is) 2004-03-11
FR2831166B1 (fr) 2004-02-27
WO2003033466A1 (fr) 2003-04-24
JP2005505621A (ja) 2005-02-24
EP1438291A1 (fr) 2004-07-21
ZA200402059B (en) 2005-03-15
DE60206068T2 (de) 2006-07-13
FR2831166A1 (fr) 2003-04-25
US20080097117A1 (en) 2008-04-24
HUP0401713A3 (en) 2012-08-28

Similar Documents

Publication Publication Date Title
CN1273451C (zh) 哌啶mch拮抗剂及其治疗肥胖症的用途
CN1056373C (zh) 含氮杂环类化合物的氟代烷氧基苄氨基衍生物的制备方法
CN1024547C (zh) 一类环胺化合物的制备方法
CN1035615C (zh) 作为新的乙酰胆碱酯酶抑制剂的芳香杂环胺类的制备方法
CN1656077A (zh) 制备手性二醇砜和二羟基酸HMGCoA还原酶抑制剂的方法
CN1098098A (zh) 哌嗪衍生物
CN1909907A (zh) 喹啉衍生物及其作为分枝杆菌抑制剂的用途
CN1636993A (zh) 新的帕罗西汀盐酸盐无水合物的制备方法
CN1688544A (zh) 作为蕈毒碱受体拮抗剂的含氟代和磺酰氨基的3,6－二取代的氮杂双环(3.1.0)己烷衍生物
CN1094723A (zh) 羧酰胺衍生物
CN1142226A (zh) 新的杂环化合物
CN100335464C (zh) 芳烷基－四氢－吡啶,其制备方法及含有它们的药物组合物
CN1910154A (zh) 用作分枝杆菌抑制剂的喹啉衍生物
CN1053923A (zh) 具有神经保护作用的3-哌啶子基-4-羟基苯并二氯吡喃衍生物
CN1117965A (zh) 取代的4-苯基-吡啶酮和4-苯基-2-烷氧基吡啶
CN1105990A (zh) 苯基链烷醇胺衍生物
CN1017622B (zh) 茚满衍生物的制备方法
CN1200939C (zh) 新的四氢吡啶,它们的制备方法以及含有它们的药物组合物
CN1910177A (zh) 取代的喹啉及其作为分枝杆菌抑制剂的用途
CN1210273C (zh) 取代的3－吡啶基－4－芳基吡咯及治疗和预防相关疾病的方法
CN1706824A (zh) 作为ccr5拮抗剂的化合物
CN1121715A (zh) 4-芳基-4-羟基-四氢吡喃类化合物和3-芳基-3-羟基-四氢呋喃类化合物作为5-脂氧合酶抑制剂
CN1155570C (zh) 新的氰基-吲哚5-羟色胺再摄取抑制剂化合物、其制备方法和含有它们的药物组合物
CN1705648A (zh) 具有ACAT抑制活性的а－苯基N－乙酰苯胺衍生物及其治疗应用
CN1107843A (zh) 二氢化茚衍生物和其制法及合成该衍生物的中间体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070905

Termination date: 20121014